FOR HEALTHCARE PROFESSIONALS
Individual results may vary.
ONCE-DAILY DOSING1
Based on once-daily application for 12 weeks.
Actual, unretouched photos of TAZORAC® patients. In clinical trials, TAZORAC improved acne with 12 weeks of use. Actual results may vary.
Patient savings may be available through Almirall Advantage.*
Keep patients informed about what it means to have and treat acne vulgaris.
*Eligible patients with commercial insurance only. Terms and conditions may apply.
TAZORAC® (tazarotene) Cream, 0.1% is indicated for the topical treatment of acne vulgaris.
TAZORAC® (tazarotene) Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris.
CONTRAINDICATIONS
TAZORAC Cream and Gel (TAZORAC) are contraindicated in individuals who have known hypersensitivity to any of its components and in Pregnancy (see Warnings and Precautions).
WARNINGS and PRECAUTIONS
Embryofetal Toxicity: TAZORAC may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. Females of child-bearing potential should have a negative pregnancy test within 2 weeks prior to initiating treatment and use an effective method of contraception during treatment.
Local Irritation: Excessive pruritus, burning, skin redness or peeling can occur. If these reactions occur, discontinue until the integrity of the skin has been restored, or consider reducing dosing frequency or in the case of psoriasis, consider switching to the lower concentration. TAZORAC should not be used on eczematous skin, as it may cause severe irritation.
Photosensitivity and Risk for Sunburn: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily. TAZORAC should be administered with caution if the patient is also taking drugs known to be photosensitizers.
ADVERSE REACTIONS
Plaque Psoriasis: Most common adverse reactions occurring in 10 to 30% of patients are pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, and skin pain.
Acne Vulgaris: Most common adverse reactions occurring in 10 to 30% of patients are desquamation, burning/stinging, dry skin, erythema, and pruritus.
The following adverse reactions have been identified during postapproval use of tazarotene. Skin and subcutaneous tissue disorders: blister, dermatitis, urticaria, skin exfoliation, skin discoloration (including skin hyperpigmentation or skin hypopigmentation), swelling at or near application sites, and pain.
For more information, please see the full Prescribing Information, including Patient Labeling, for TAZORAC Cream or TAZORAC Gel.
REFERENCE: 1. TAZORAC Cream and Gel 0.1% and 0.05% Prescribing Information; August 2019.